In the phase 3 CheckMate-9ER trial of patients with advanced renal cell carcinoma (aRCC), first-line treatment with nivolumab plus cabozantinib demonstrated superior progression-free survival (PFS), overall survival (OS), and objective response rates (ORR) compared with sunitinib.
In the KEYNOTE-177 study, reported at the ESMO 2020 Virtual Meeting, pembrolizumab monotherapy significantly improved progression-free survival (PFS) vs standard chemotherapy as first-line treatment in patients with microsatellite instability-high and/or deficient mismatch repair metastatic colorectal cancer (mCRC).
In a study reported at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 ESMO Meeting, first-line cemiplimab monotherapy significantly improved overall survival (OS) and progression-free (PFS) vs platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 ≥50%. Despite a high crossover rate, the study provided a rationale for cemiplimab as a new treatment option for this patient population.
At ESMO Virtual Congress 2020, the results from three randomized phase 3 clinical trials — CheckMate 649, ATTRACTION-4, and KEYNOTE-590 — made one thing clear: Immunotherapy benefits patients with gastric and esophageal cancers. As for the adjuvant setting, which had no standard of care, the results from the phase 3 CheckMate 577 trial point to nivolumab as a new option.
PARP inhibition continues to steal the spotlight in advanced ovarian cancer, even in the absence of pivotal trial data. Findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 showed a significant benefit for PARP inhibition earlier in the cancer pathway, offering hope for more long-term survivors, while other treatment paradigms such as immunotherapy failed again to make headway against the disease.